Point72 Hong Kong’s Intellia Therapeutics NTLA Stock Holding History

Point72 Hong Kong’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-126	Closed	-$2.58K	–	548
2024 Q3	$2.58K	Buy	+126	New	+$2.9K	﹤0.01%	436
2022 Q4	–	Sell	-1,097	Closed	-$61K	–	1172
2022 Q3	$61K	Buy	+1,097	New	+$68.1K	﹤0.01%	1371
2022 Q2	–	Sell	-2,270	Closed	-$165K	–	2268
2022 Q1	$165K	Buy	+2,270	New	+$192K	0.01%	1018
2021 Q4	–	Sell	-866	Closed	-$116K	–	2229
2021 Q3	$116K	Buy	+866	New	+$131K	﹤0.01%	1308
2020 Q4	–	Sell	-4,371	Closed	-$87K	–	1952
2020 Q3	$87K	Buy	+4,371	New	+$91.1K	0.01%	586
2019 Q2	–	Sell	-270	Closed	-$5K	–	1317
2019 Q1	$5K	Buy	270 +193	+251%	+$2.88K	﹤0.01%	819
2018 Q4	$1K	Sell	77 -2,006	-96%	-$37.3K	﹤0.01%	804
2018 Q3	$60K	Buy	2,083 +1,835	+740%	+$53.4K	0.02%	432
2018 Q2	$7K	Sell	248 -2,817	-92%	-$68.2K	﹤0.01%	680
2018 Q1	$65K	Buy	+3,065	New	+$75.4K	0.03%	403

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Hong Kong's NTLA Position: Q4 2024 in Review

Point72 Hong Kong sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 126 shares — an estimated $2.58K sold.

Point72 Hong Kong first reported a position in NTLA in Q1 2018 and held it in 10 quarters. The position peaked at $165K in Q1 2022. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

Point72 Hong Kong reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
Point72 Hong Kong sold 126 Intellia Therapeutics shares in Q4 2024, an estimated $2.58K.
Point72 Hong Kong first reported a position in Intellia Therapeutics in Q1 2018 and held it in 10 quarters.
Point72 Hong Kong's Intellia Therapeutics position peaked at $165K in Q1 2022.
293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Point72 Hong Kong's 13F filing for Q4 2024, filed 14 Feb 2025.